PropertyValue
?:definition
  • The unique identifier assigned to the arm of the Molecular Analysis for Therapy Choice (MATCH) phase II clinical trial that is investigating treatment with crizotinib in patients with tumors that have ALK translocations, excluding adenocarcinomas of lung and anaplastic large cell lymphomas.
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C5401189_NCI>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C5401189_NCI>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all